The epithelial-to-mesenchymal transition marker that is highly expressed in primary and metastatic cancers, CD44 [28], was significantly upregulated where a fibroblast stroma was present compared to a bone stroma (∼2-fold) (p < 0.0005) (Fig. 5D). Here, CD44 is linked to metastatic malignant neoplasm.